BR0111878A - N-ureido-(heterociclo-alquil)-piperidinas como moduladores da atividade de receptores de quimiocinas - Google Patents
N-ureido-(heterociclo-alquil)-piperidinas como moduladores da atividade de receptores de quimiocinasInfo
- Publication number
- BR0111878A BR0111878A BR0111878-1A BR0111878A BR0111878A BR 0111878 A BR0111878 A BR 0111878A BR 0111878 A BR0111878 A BR 0111878A BR 0111878 A BR0111878 A BR 0111878A
- Authority
- BR
- Brazil
- Prior art keywords
- modulators
- piperidines
- ureido
- receptor activity
- heterocycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
"N-UREIDO-(HETEROCICLO-ALQUIL)-PIPERIDINAS COMO MODULADORES DA ATIVIDADE DE RECEPTORES DE QUIMIOCINAS". O presente pedido de patente descreve moduladores de CCR3 da fórmula (I) ou suas formas de sais de uso farmacêutico, úteis para a prevenção de asma e outras doenças alérgicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21521500P | 2000-06-30 | 2000-06-30 | |
PCT/US2001/020989 WO2002002525A2 (en) | 2000-06-30 | 2001-06-29 | N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0111878A true BR0111878A (pt) | 2005-05-24 |
Family
ID=22802114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0111878-1A BR0111878A (pt) | 2000-06-30 | 2001-06-29 | N-ureido-(heterociclo-alquil)-piperidinas como moduladores da atividade de receptores de quimiocinas |
Country Status (12)
Country | Link |
---|---|
US (2) | US6627629B2 (pt) |
EP (1) | EP1296978A2 (pt) |
JP (1) | JP2004517805A (pt) |
CN (1) | CN1440402A (pt) |
AR (1) | AR034257A1 (pt) |
AU (1) | AU2001273129A1 (pt) |
BR (1) | BR0111878A (pt) |
CA (1) | CA2413245A1 (pt) |
HK (1) | HK1054032A1 (pt) |
IL (1) | IL153123A0 (pt) |
MX (1) | MXPA02012712A (pt) |
WO (1) | WO2002002525A2 (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1440402A (zh) * | 2000-06-30 | 2003-09-03 | 布里斯托尔-迈尔斯斯奎布公司 | 作为趋化因子受体活性调节剂的n-脲基杂环烷基-哌啶 |
US6434344B1 (en) | 2001-02-28 | 2002-08-13 | Toshiba Tec Kabushiki Kaisha | Image forming apparatus having a transfer device for transferring a toner image and having a bias voltage controller |
TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
US6835841B2 (en) | 2002-09-13 | 2004-12-28 | Bristol-Myers Squibb Company | Asymmetric catalytic hydrogenation process for preparation of chiral cyclic β-aminoesters |
US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
SE0400208D0 (sv) * | 2004-02-02 | 2004-02-02 | Astrazeneca Ab | Chemical compounds |
WO2006062982A2 (en) * | 2004-12-07 | 2006-06-15 | Locus Pharmaceuticals, Inc. | Urea inhibitors of map kinases |
US7612200B2 (en) * | 2004-12-07 | 2009-11-03 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8067457B2 (en) * | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
WO2007053499A2 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
US20100016289A1 (en) * | 2005-11-01 | 2010-01-21 | Kevin Sprott | Compounds Useful as Antagonists of CCR2 |
WO2007081690A2 (en) * | 2006-01-04 | 2007-07-19 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
TW200812582A (en) * | 2006-04-06 | 2008-03-16 | Astrazeneca Ab | Medicaments |
EP2119702A4 (en) | 2007-01-31 | 2010-12-08 | Dainippon Sumitomo Pharma Co | amide derivative |
JP2010523523A (ja) * | 2007-04-03 | 2010-07-15 | ノバルティス アーゲー | 新規方法 |
WO2009015166A1 (en) * | 2007-07-24 | 2009-01-29 | Bristol-Myers Squibb Company | Piperidine derivatives as modulators of chemokine receptor activity |
WO2010069979A1 (en) * | 2008-12-16 | 2010-06-24 | Nycomed Gmbh | Pyran derivatives as ccr3 modulators |
EP2398789B1 (en) | 2009-02-20 | 2014-03-19 | Merck Sharp & Dohme Corp. | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2010122580A2 (en) | 2009-04-24 | 2010-10-28 | Cadila Healthcare Limited | Novel compounds as inhibitors of renin |
WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
CA2765527A1 (en) | 2009-06-24 | 2010-12-29 | Satoshi Suetsugu | N-substituted-cyclic amino derivative |
CA2820044A1 (en) | 2010-12-08 | 2012-06-14 | Lycera Corporation | Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
CA2820065C (en) | 2010-12-08 | 2019-04-02 | Lycera Corporation | Pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
US9169199B2 (en) | 2010-12-08 | 2015-10-27 | Lycera Corporation | Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
NZ618795A (en) * | 2011-05-13 | 2015-07-31 | Array Biopharma Inc | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors |
US9920012B2 (en) | 2012-06-08 | 2018-03-20 | Lycera Corporation | Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
WO2013185048A2 (en) | 2012-06-08 | 2013-12-12 | Lycera Corporation | Heterocyclic guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
WO2013185046A1 (en) | 2012-06-08 | 2013-12-12 | Lycera Corporation | Saturated acyl guanid1ne for inhibition of f1f0-atpase |
ME02879B (me) | 2012-11-13 | 2018-04-20 | Array Biopharma Inc | Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola |
US9790210B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078323A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
EP3080087B1 (en) | 2013-12-10 | 2019-05-22 | Lycera Corporation | N-substituted pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
CA2931850A1 (en) | 2013-12-10 | 2015-06-18 | Lycera Corporation | Alkylpyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
AU2014363904B2 (en) | 2013-12-10 | 2018-10-04 | Lycera Corporation | Trifluoromethyl pyrazolyl guanidine F1Fo-ATPase inhibitors and therapeutic uses thereof |
MX2016014945A (es) | 2014-05-15 | 2017-03-27 | Array Biopharma Inc | 1- ((3s,4r) -4- (3-fluorofenil) -1- (2-metoxietil) pirrolidin-3-il) -3- (4-metil-3- (2-metilpirimidin-5-il) -1-fenil-1h-pirazol-5-il) urea como inhibidor de trka cinasa. |
PT3297438T (pt) * | 2015-05-21 | 2022-01-25 | Chemocentryx Inc | Moduladores de ccr2 |
JP6812059B2 (ja) * | 2015-07-07 | 2021-01-13 | 塩野義製薬株式会社 | TrkA阻害活性を有する複素環誘導体 |
JP7453139B2 (ja) | 2017-09-25 | 2024-03-19 | ケモセントリックス,インコーポレイティド | ケモカイン受容体2(ccr2)アンタゴニスト及びpd-1/pd-l1阻害剤を使用した併用療法 |
JP7442141B2 (ja) | 2018-01-08 | 2024-03-04 | ケモセントリックス,インコーポレイティド | Ccr2アンタゴニストによる固形腫瘍の治療方法 |
WO2019179362A1 (zh) * | 2018-03-19 | 2019-09-26 | 四川科伦博泰生物医药股份有限公司 | 脒类和胍类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3461120A (en) | 1965-09-27 | 1969-08-12 | Sterling Drug Inc | N-((1-piperidyl)-lower-alkyl)-n-((3-,2-,and 1-indolyl)-lower-alkyl) amines |
JP2826826B2 (ja) | 1988-04-11 | 1998-11-18 | 日本ケミファ株式会社 | アルキレンジアミン誘導体 |
GB8816365D0 (en) | 1988-07-08 | 1988-08-10 | Pfizer Ltd | Therapeutic agents |
IE903957A1 (en) | 1989-11-06 | 1991-05-08 | Sanofi Sa | Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present |
IL99320A (en) | 1990-09-05 | 1995-07-31 | Sanofi Sa | Arylalkylamines, their preparation and pharmaceutical preparations containing them |
GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
WO1994022846A1 (en) | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Compounds enhancing antitumor activity of other cytotoxic agents |
DK60693D0 (da) | 1993-05-26 | 1993-05-26 | Novo Nordisk As | Kemiske forbindelser, deres fremstilling og anvendelse |
DK60893D0 (da) | 1993-05-26 | 1993-05-26 | Novo Nordisk As | Piperidinderivater, deres fremstilling og anvendelse |
US5547966A (en) | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
GB9326611D0 (en) | 1993-12-31 | 1994-03-02 | Fujisawa Pharmaceutical Co | New compound |
EP0739336B1 (en) | 1994-01-13 | 1998-08-26 | MERCK SHARP & DOHME LTD. | Gem-disubstituted azacyclic tachykinin antagonists |
US5661161A (en) | 1994-09-29 | 1997-08-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
US5668151A (en) | 1995-06-07 | 1997-09-16 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: piperidine derivatives |
AU1117497A (en) | 1995-11-13 | 1997-06-05 | Albany Medical College | Analgesic compounds and uses thereof |
GB9523526D0 (en) | 1995-11-17 | 1996-01-17 | Zeneca Ltd | Therapeutic compounds |
AU704139B2 (en) | 1995-11-22 | 1999-04-15 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6087357A (en) | 1995-12-18 | 2000-07-11 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives as tachykinin antagonists |
TW531537B (en) | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
AU1208397A (en) | 1995-12-28 | 1997-07-28 | Takeda Chemical Industries Ltd. | Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists |
AU712504B2 (en) | 1996-01-30 | 1999-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5688955A (en) | 1996-03-08 | 1997-11-18 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
EP0891361A1 (en) | 1996-04-03 | 1999-01-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2000507595A (ja) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシルプロテイントランスフェラーゼの阻害剤 |
JP2000504024A (ja) | 1996-04-03 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
AU721952B2 (en) | 1996-04-03 | 2000-07-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2000509371A (ja) | 1996-04-03 | 2000-07-25 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
CA2249665A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036896A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2000507591A (ja) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
CA2250204A1 (en) | 1996-04-03 | 1997-10-09 | Neville J. Anthony | Inhibitors of farnesyl-protein transferase |
WO1997036876A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2249601A1 (en) | 1996-04-03 | 1997-10-23 | Thorsten E. Fisher | Inhibitors of farnesyl-protein transferase |
GB9612884D0 (en) | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
US5972966A (en) | 1996-12-05 | 1999-10-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5962462A (en) | 1996-12-13 | 1999-10-05 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
WO1998025617A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
WO1998025604A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
JP2001508798A (ja) | 1997-01-21 | 2001-07-03 | メルク エンド カンパニー インコーポレーテッド | ケモカインレセプター活性のモジュレーターとしての3,3−二置換ピペリジン類 |
AU7371998A (en) | 1997-05-07 | 1998-11-27 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
US6001836A (en) | 1997-05-28 | 1999-12-14 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: cyanoguanidine derivatives |
US5889016A (en) | 1997-06-26 | 1999-03-30 | Bristol-Myers Squibb Company | Dihydropyrimidone derivatives as NPY antagonists |
JP2002510327A (ja) | 1997-07-25 | 2002-04-02 | メルク エンド カンパニー インコーポレーテッド | 環状アミンケモカイン受容体活性調節剤 |
IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
CA2298813A1 (en) | 1997-08-28 | 1999-03-04 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
WO1999054321A1 (en) | 1998-04-21 | 1999-10-28 | Aventis Pharma Limited | Substituted diamines and their use as cell adhesion inhibitors |
SE9802209D0 (sv) | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
CA2350730A1 (en) | 1998-12-18 | 2000-06-22 | George V. Delucca | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
CA2346933A1 (en) | 1998-12-18 | 2000-06-22 | Dupont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
US6331541B1 (en) | 1998-12-18 | 2001-12-18 | Soo S. Ko | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
AU2056700A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity |
US6486180B1 (en) | 1998-12-18 | 2002-11-26 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
US6331545B1 (en) | 1998-12-18 | 2001-12-18 | Soo S. Ko | Heterocycyclic piperidines as modulators of chemokine receptor activity |
US6492400B1 (en) * | 1998-12-18 | 2002-12-10 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
CA2347770A1 (en) | 1998-12-18 | 2000-06-22 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
AU760174B2 (en) * | 1999-02-09 | 2003-05-08 | Bristol-Myers Squibb Company | Lactam inhibitors of FXa and method |
CN1440402A (zh) * | 2000-06-30 | 2003-09-03 | 布里斯托尔-迈尔斯斯奎布公司 | 作为趋化因子受体活性调节剂的n-脲基杂环烷基-哌啶 |
KR100579352B1 (ko) * | 2001-11-30 | 2006-05-12 | 에프. 호프만-라 로슈 아게 | Ccr-3 수용체 길항제 ⅶ |
-
2001
- 2001-06-29 CN CN01812052A patent/CN1440402A/zh active Pending
- 2001-06-29 JP JP2002507782A patent/JP2004517805A/ja active Pending
- 2001-06-29 AR ARP010103133A patent/AR034257A1/es unknown
- 2001-06-29 EP EP01952369A patent/EP1296978A2/en not_active Withdrawn
- 2001-06-29 BR BR0111878-1A patent/BR0111878A/pt not_active Application Discontinuation
- 2001-06-29 CA CA002413245A patent/CA2413245A1/en not_active Abandoned
- 2001-06-29 IL IL15312301A patent/IL153123A0/xx unknown
- 2001-06-29 US US09/895,138 patent/US6627629B2/en not_active Expired - Lifetime
- 2001-06-29 MX MXPA02012712A patent/MXPA02012712A/es unknown
- 2001-06-29 WO PCT/US2001/020989 patent/WO2002002525A2/en not_active Application Discontinuation
- 2001-06-29 AU AU2001273129A patent/AU2001273129A1/en not_active Abandoned
-
2003
- 2003-07-10 US US10/617,303 patent/US6949546B2/en not_active Expired - Lifetime
- 2003-09-05 HK HK03106350.8A patent/HK1054032A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20040058961A1 (en) | 2004-03-25 |
US6949546B2 (en) | 2005-09-27 |
HK1054032A1 (zh) | 2003-11-14 |
JP2004517805A (ja) | 2004-06-17 |
EP1296978A2 (en) | 2003-04-02 |
WO2002002525A3 (en) | 2002-08-29 |
AR034257A1 (es) | 2004-02-18 |
CN1440402A (zh) | 2003-09-03 |
US6627629B2 (en) | 2003-09-30 |
AU2001273129A1 (en) | 2002-01-14 |
MXPA02012712A (es) | 2003-04-25 |
IL153123A0 (en) | 2003-06-24 |
CA2413245A1 (en) | 2002-01-10 |
WO2002002525A2 (en) | 2002-01-10 |
US20030032654A1 (en) | 2003-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0111878A (pt) | N-ureido-(heterociclo-alquil)-piperidinas como moduladores da atividade de receptores de quimiocinas | |
TR200101859T2 (tr) | Kemokin alıcı aktivitesinin modülatörleri olarak N-üreidoalkil-piperidinler | |
WO2001098268A3 (en) | Piperidine amides as modulators of chemokine receptor activity | |
ATE302606T1 (de) | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren | |
WO2003024401A3 (en) | Piperizinones as modulators of chemokine receptor activity | |
MY131890A (en) | Piperidine compounds | |
NO20033566D0 (no) | Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler | |
BR0112756A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto | |
BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
SE0001899D0 (sv) | New compounds | |
BR0214705A (pt) | Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit | |
UY27368A1 (es) | Nuevos compuestos | |
WO2006044362A3 (en) | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | |
SE0301653D0 (sv) | Novel compounds | |
NO20045486L (no) | Nye forbindelser og deres anvendelse | |
BR0210028A (pt) | Agentes antibacterianos | |
WO2001028987A8 (en) | Benzylcycloalkyl amines as modulators of chemokine receptor activity | |
BR0318278A (pt) | compostos de éter aminocicloexìlico e usos dos mesmo | |
BR0209440A (pt) | Sulfonamidas | |
SE0101932D0 (sv) | Pharmaceutical combinations | |
BR0212069A (pt) | Agentes antidiabéticos orais | |
WO2001098270A3 (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
WO2001098269A3 (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
BR0210912A (pt) | Compostos e composições como inibidores de catepsina | |
BR0103725A (pt) | Poliuréias à base de ipdi, hdi, seus isocianuratos e aminas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |